Literature DB >> 23810890

Dabigatran's 'real-world' data about risk of myocardial infarction and gastrointestinal bleeding contradicts with randomized trials.

Ilke Sipahi, Seden Celik, Ahmet Akyol.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23810890     DOI: 10.1016/j.jacc.2013.05.066

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  3 in total

Review 1.  Bypass grafting versus percutaneous intervention in multivessel coronary disease: the current state.

Authors:  Ilke Sipahi
Journal:  Curr Cardiol Rep       Date:  2015-02       Impact factor: 2.931

2.  Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison.

Authors:  Yoon K Loke; Shiva Pradhan; Jessica Ka-Yan Yeong; Chun Shing Kwok
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

Review 3.  Oral direct thrombin inhibition: a double-edged sword?

Authors:  Gabriele Fragasso; Angelo Corti; Ferdinando Loiacono; Alberto Margonato; Armando D'Angelo
Journal:  Heart Lung Vessel       Date:  2015
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.